Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They can have mine for $2 each :)
I agree we figured that 2 weeks ago a buyout should mean APPY $2.00 plus a share IMO
right now we do not meet the requirements to stay as a NASDAQ listed stock. One thing had crossed my mind that they won't have to do a reverse split if Strand acquires the shares at a price that makes us meet those requirements. what if they agree that they will buy the shares at 2-3 bucks? Thoughts or could this not happen?
APPY news~ Bangalore-based Strand Life Sciences Pvt Ltd, which focuses on clinical genomics and research in biotechnology, is going through a reverse merger with a little-known NASDAQ-listed firm in the second such transaction by an Indian company to go public overseas.
In the process, it will become only the second Indian healthcare and life sciences firm to be listed in the US after drugmaker Dr ....
Read more at:
http://www.vccircle.com/news/pharmaceuticals/2016/01/29/strand-life-sciences-get-listed-nasdaq-through-reverse-merger
Dang I would hate to be short or not holding APPY shares when this get's big PR ahead!
Bangalore-based Strand Life Sciences Pvt Ltd, which focuses on clinical genomics and research in biotechnology, is going through a reverse merger with a little-known NASDAQ-listed firm in the second such transaction by an Indian company to go public overseas.
In the process, it will become only the second Indian healthcare and life sciences firm to be listed in the US after drugmaker Dr ....
Read more at:
http://www.vccircle.com/news/pharmaceuticals/2016/01/29/strand-life-sciences-get-listed-nasdaq-through-reverse-merger
Looks like Strand is going public by reverse merging into APPY. Should mean big $$$ ahead!
http://www.vccircle.com/news/pharmaceuticals/2016/01/29/strand-life-sciences-get-listed-nasdaq-through-reverse-merger
Sounds like the APPY merger is done? Can you copy and paste it I tried it would not work?
ATTY shorts testing here on green IMO. Dang huge mistake.
JMO
One can imagine how tiny the float is on this.
60,000,000 shares authorized;
30,990,029 shares issued and outstanding
Very soon IMO
APPY
I'm very comfortable adding in this price range as I can't see it going any lower. The RSI is so oversold right now and with this merger news to start taking place in April it could very easily go bananas soon.
Nice! Looks like we have buyers hidden here on the APPY bid. I love it.
Yeah I picked up another 2k shares this morning at .265 so far.
APPY ~ CASTLE ROCK, Colo., Jan. 26, 2016 /PRNewswire/ -- Venaxis®, Inc. (Nasdaq: APPY), announced today that it has entered into a series of agreements for a transaction with Strand Life Sciences Private Limited (Strand LS) and its shareholders. Strand LS is a privately-held, global genomics and bioinformatics company. Strand LS operates clinical reference labs in the US through its wholly owned subsidiary Strand Genomics, Inc., (Strand U.S.) and directly in India, providing testing and lab services in India and other world-wide markets. Strand LS has commercialized a next generation sequencing (NGS) based, targeted, multi-gene, pan-cancer diagnostic panel in select international markets and has engaged in initial commercialization activities in the United States.
Assuming participation by 100% of the Strand LS shareholders, the effect of the transaction will be that Strand LS shareholders and the employees and directors who are option-holders in Strand LS will own directly and beneficially approximately 68% of the combined enterprise and the current shareholders of Venaxis will own approximately 32%. Due to Indian tax and financial regulations, the transaction is being structured as purchases, by Venaxis, of the Strand LS shares from the Strand LS shareholders, followed by an immediate re-investment of those sale proceeds, by the Strand LS shareholders, into Venaxis Common Stock.
To comply with certain long-term holding period requirements under Indian tax law, the transaction is expected to be completed in two closings. The first closing will occur upon receipt of the necessary approvals from the Venaxis shareholders, receipt of all other required approvals and satisfaction of identified closing conditions. The second closing will occur approximately six months later. At each closing, Venaxis will enter into resale registration rights agreements with the Strand LS shareholders participating in such closing. The boards of each company have unanimously approved the transaction, however this transaction is subject to Venaxis shareholder approval.
At the first closing, Venaxis will own a majority of the shares of Strand LS, will change its name to Strand Life Sciences, and will change its NASDAQ trading symbol. As part of the first closing, following Venaxis shareholder approval, a Venaxis subsidiary will enter into an asset purchase agreement with Strand U.S. in which it will acquire substantially all of the assets and liabilities of Strand U.S. in exchange for cash consideration paid to Strand U.S.
Advancing to the execution of the agreements with Strand LS, its shareholders and Strand U.S. represents the outcome of an extensive strategic process initiated by Venaxis in early 2015. Venaxis has also commenced, and expects to continue to attempt to locate a partner or other third-party interested in advancing development and or commercial activities of the Venaxis appendicitis portfolio. Aligning Strand Life Sciences' proven technological expertise in genomic profiling, bioinformatics and data curation with Venaxis' financial resources, NASDAQ public listing and key management personnel provides an opportunity for Strand Life Sciences to continue to commercialize its global business model towards what is believed to be a valuable enterprise for the combined shareholders.
Following approval by the Venaxis shareholders and satisfaction of the other closing conditions, at the first closing, Dr. Vijay Chandru, the co-founder and current Executive Chairman of Strand LS, will serve as Executive Chairman of the combined company's Board of Directors, Steve Lundy will become the Chief Executive Officer of the combined company and Jeff McGonegal will continue as CFO. The initial combined board will consist of seven members with four from Strand LS and three from Venaxis.
Commenting on the transaction, Dr. Vijay Chandru said, "On behalf of the Strand LS shareholders, we believe that this transaction represents an attractive opportunity for Strand Life Sciences, as an agile innovator in clinical genomics, to combine forces with Venaxis, a public company in the United States with experienced executives and board members to help it rapidly expand market adoption of StrandAdvantage™ and other future product offerings."
"We are pleased to announce this transaction and are excited by the significant opportunity we believe it presents for shareholders of Venaxis and Strand LS," said Steve Lundy, Chief Executive Officer of Venaxis, Inc. "The combined company will benefit from Strand Life Sciences' 15 year successful history of technological expertise in genomic profiling, bioinformatics and data curation. Our initial focus will be to improve patient outcomes through the use of the StrandAdvantage pan-cancer gene panel, which was commercially launched in the United States in 2015. The combined company is expected to be focused on the continued commercialization of StrandAdvantage, as well as the development of additional oncology-related diagnostics."
Raymond James & Associates, Inc. and Oppenheimer & Co. Inc. are acting as joint financial advisors to Strand LS and Baker & Hostetler LLP is acting as legal counsel for Strand LS. Ballard Spahr LLP is acting as legal counsel to Venaxis.
Conference Call
Venaxis and Strand LS will host an investor conference call to discuss the transaction on Wednesday, January 27, 2016, at 8:30 a.m. ET. The conference call will be hosted by Steve Lundy, President and CEO of Venaxis, Inc.
APPY gets a nod from Daniel Ward at seekingalpha as one of the top biotech picks for 2016:
Venaxis (NASDAQ:APPY) - 15% Allocation: Venaxis is a new name to my Top Value Biotechs list. Venaxis is an in vitro diagnostic company developing and commercializing its unique multi-biomarker diagnostic test, the APPY1 test. While the name popped 50% within a few days after I initially discussed it in a spotlight piece back in April, the name has lagged since. When I wrote about the name in late July, I expected the company to would likely follow up with a Q3 business update on the path forward with APPY1, but the company has been extremely quiet. Two main points I would like to highlight are as follows:
1. Sale of Headquarters: The only piece of news that has come out since the last business update in late June is the fact that the company sold its corporate headquarters in Castle Rock, Colorado. The company announced through the 8-K filed on October 21st that it sold its headquarters to Niebur Golf Development, LLC for $4,053,000 with closing expected to take place in December. The company expects to generate $1.7 million in net cash from this sale after expenses and mortgage payoffs. Post-closing the company will just pay a lease payment of $22,000 per month. Why would a company sell its headquarters? The sale cleans up the balance sheet in that the company will get $990,500 in cash at close and will receive a note receivable for the remainder of money owed. The company can pay off debt and is now only committed to a lease that can be ended with 60 days' notice with the ability to provide notice starting January 31.
2. What is Going on at Venaxis?: Other than the sale of the headquarters, news has been nonexistent. Let's think critically about the one piece of news we have gotten. Cleaning up the balance sheet by taking care of selling the company's main property and equipment is something I view as preparing the company for a strategic action. Additionally supporting this line of thinking is the fact that the company has not had a business update call for six months, which is unheard of and signals to me that they are in the process of a substantial strategic action. Even when considering cash burn of $1.35 million per quarter (the level of cash burn management has guided previously) or even cash burn up to $2.00 million given that we are generally unsure what exactly the company is doing, cash at year end would still likely be between $16.9 and $17.6 million based on the Q3 end cash balance. Adding the $990,500 in upfront cash from the real estate deal would bring this cash estimate up to between $17.9 and $18.6 million. The company may use some of the cash to pay off the mortgage note, but this would not affect shareholder equity. Shareholder equity was $18.9 million as of Q3 end. Based on a market cap of only $9.6 million, the stock currently trades at only 0.5x-0.6x based on book value and cash value. Way back in the June 2015 business update, the company had noted it was reviewing a variety of business opportunities. While I had initially thought the company would just be doing an asset buy in the in-vitro diagnostics space, the company's more or less silence over the past 6 months makes me think they could be reviewing a more substantial strategic action like a reverse merger. If the company were just looking at a more minor strategic action, I would expect them to keep investors much more updated on what was going on with other parts of the business like APPY1 and APPY2.
Concluding Thoughts On Venaxis: Ultimately, given the lack of communication with shareholders, it's hard to predict exactly what is happening at Venaxis. While I think the sale of the headquarters combined with the company dropping off the radar in terms of updates for six months means that the company may be completing a more substantial strategic alternative (such as a reverse merger) that was identified through the business development review, I want to acknowledge that this is merely conjecture as there are a wide variety of things that could be going on at Venaxis. While I do think we may very well see a strategic alternative, it's also possible that the next update brings disappointment in terms of lack of progress with APPY1 and APPY2. With the stock trading at 0.5x-0.6x book and roughly the same ratio based on cash, I think downside is muted though given the balance sheet even if the company provides a disappointing, lackluster update.
http://seekingalpha.com/article/3779066-biotech-weekly-top-value-biotech-picks-for-2016
Today is the frontloading day for APPY. Last weekend seekingalpha chose APPY as one of the top biotech stocks to own in 2016. That was before this weeks news.
Adding APPY here.
Serious dumpage went down.
He buys stocks also.
I don't know much of anything about the guy to be honest just saw on twitter that he tweeted it was on his watch list.
The .25 leftover gap from yesterday's spike got filled and I thought Syke's only shorted stocks. Do you have any link to Syke's position?
LMAO I get it. I love adding APPY cheapies.
Just not before im fully loaded lol.
Correct. APPY is on many radars we could run huge any day now.
So if I'm reading the 8K correctly they plan start buying the shares no earlier than April of this year. So we have a little bit of time to stock pile shares.
No. That is great considering we also have Dave over at seeking alpha calling APPY one of his top biotech picks for 2016.
Did you see that Tim Sykes added APPY to his watchlist.
I'm going to have some more funds to buy more tomorrow. I can't see this going much lower
Patience APPY has a thin ask. More news on the way.
Holy drop batman. This one is slipping fast.
red out of the gate. my other bigs are flying. FB, MT, GOOG,
APPY gets a nod from Daniel Ward at seekingalpha as one of the top biotech picks for 2016:
Venaxis (NASDAQ:APPY) - 15% Allocation: Venaxis is a new name to my Top Value Biotechs list. Venaxis is an in vitro diagnostic company developing and commercializing its unique multi-biomarker diagnostic test, the APPY1 test. While the name popped 50% within a few days after I initially discussed it in a spotlight piece back in April, the name has lagged since. When I wrote about the name in late July, I expected the company to would likely follow up with a Q3 business update on the path forward with APPY1, but the company has been extremely quiet. Two main points I would like to highlight are as follows:
1. Sale of Headquarters: The only piece of news that has come out since the last business update in late June is the fact that the company sold its corporate headquarters in Castle Rock, Colorado. The company announced through the 8-K filed on October 21st that it sold its headquarters to Niebur Golf Development, LLC for $4,053,000 with closing expected to take place in December. The company expects to generate $1.7 million in net cash from this sale after expenses and mortgage payoffs. Post-closing the company will just pay a lease payment of $22,000 per month. Why would a company sell its headquarters? The sale cleans up the balance sheet in that the company will get $990,500 in cash at close and will receive a note receivable for the remainder of money owed. The company can pay off debt and is now only committed to a lease that can be ended with 60 days' notice with the ability to provide notice starting January 31.
2. What is Going on at Venaxis?: Other than the sale of the headquarters, news has been nonexistent. Let's think critically about the one piece of news we have gotten. Cleaning up the balance sheet by taking care of selling the company's main property and equipment is something I view as preparing the company for a strategic action. Additionally supporting this line of thinking is the fact that the company has not had a business update call for six months, which is unheard of and signals to me that they are in the process of a substantial strategic action. Even when considering cash burn of $1.35 million per quarter (the level of cash burn management has guided previously) or even cash burn up to $2.00 million given that we are generally unsure what exactly the company is doing, cash at year end would still likely be between $16.9 and $17.6 million based on the Q3 end cash balance. Adding the $990,500 in upfront cash from the real estate deal would bring this cash estimate up to between $17.9 and $18.6 million. The company may use some of the cash to pay off the mortgage note, but this would not affect shareholder equity. Shareholder equity was $18.9 million as of Q3 end. Based on a market cap of only $9.6 million, the stock currently trades at only 0.5x-0.6x based on book value and cash value. Way back in the June 2015 business update, the company had noted it was reviewing a variety of business opportunities. While I had initially thought the company would just be doing an asset buy in the in-vitro diagnostics space, the company's more or less silence over the past 6 months makes me think they could be reviewing a more substantial strategic action like a reverse merger. If the company were just looking at a more minor strategic action, I would expect them to keep investors much more updated on what was going on with other parts of the business like APPY1 and APPY2.
Concluding Thoughts On Venaxis: Ultimately, given the lack of communication with shareholders, it's hard to predict exactly what is happening at Venaxis. While I think the sale of the headquarters combined with the company dropping off the radar in terms of updates for six months means that the company may be completing a more substantial strategic alternative (such as a reverse merger) that was identified through the business development review, I want to acknowledge that this is merely conjecture as there are a wide variety of things that could be going on at Venaxis. While I do think we may very well see a strategic alternative, it's also possible that the next update brings disappointment in terms of lack of progress with APPY1 and APPY2. With the stock trading at 0.5x-0.6x book and roughly the same ratio based on cash, I think downside is muted though given the balance sheet even if the company provides a disappointing, lackluster update.
http://seekingalpha.com/article/3779066-biotech-weekly-top-value-biotech-picks-for-2016
APPY ~ CASTLE ROCK, Colo., Jan. 26, 2016 /PRNewswire/ -- Venaxis®, Inc. (Nasdaq: APPY), announced today that it has entered into a series of agreements for a transaction with Strand Life Sciences Private Limited (Strand LS) and its shareholders. Strand LS is a privately-held, global genomics and bioinformatics company. Strand LS operates clinical reference labs in the US through its wholly owned subsidiary Strand Genomics, Inc., (Strand U.S.) and directly in India, providing testing and lab services in India and other world-wide markets. Strand LS has commercialized a next generation sequencing (NGS) based, targeted, multi-gene, pan-cancer diagnostic panel in select international markets and has engaged in initial commercialization activities in the United States.
Assuming participation by 100% of the Strand LS shareholders, the effect of the transaction will be that Strand LS shareholders and the employees and directors who are option-holders in Strand LS will own directly and beneficially approximately 68% of the combined enterprise and the current shareholders of Venaxis will own approximately 32%. Due to Indian tax and financial regulations, the transaction is being structured as purchases, by Venaxis, of the Strand LS shares from the Strand LS shareholders, followed by an immediate re-investment of those sale proceeds, by the Strand LS shareholders, into Venaxis Common Stock.
To comply with certain long-term holding period requirements under Indian tax law, the transaction is expected to be completed in two closings. The first closing will occur upon receipt of the necessary approvals from the Venaxis shareholders, receipt of all other required approvals and satisfaction of identified closing conditions. The second closing will occur approximately six months later. At each closing, Venaxis will enter into resale registration rights agreements with the Strand LS shareholders participating in such closing. The boards of each company have unanimously approved the transaction, however this transaction is subject to Venaxis shareholder approval.
At the first closing, Venaxis will own a majority of the shares of Strand LS, will change its name to Strand Life Sciences, and will change its NASDAQ trading symbol. As part of the first closing, following Venaxis shareholder approval, a Venaxis subsidiary will enter into an asset purchase agreement with Strand U.S. in which it will acquire substantially all of the assets and liabilities of Strand U.S. in exchange for cash consideration paid to Strand U.S.
Advancing to the execution of the agreements with Strand LS, its shareholders and Strand U.S. represents the outcome of an extensive strategic process initiated by Venaxis in early 2015. Venaxis has also commenced, and expects to continue to attempt to locate a partner or other third-party interested in advancing development and or commercial activities of the Venaxis appendicitis portfolio. Aligning Strand Life Sciences' proven technological expertise in genomic profiling, bioinformatics and data curation with Venaxis' financial resources, NASDAQ public listing and key management personnel provides an opportunity for Strand Life Sciences to continue to commercialize its global business model towards what is believed to be a valuable enterprise for the combined shareholders.
Following approval by the Venaxis shareholders and satisfaction of the other closing conditions, at the first closing, Dr. Vijay Chandru, the co-founder and current Executive Chairman of Strand LS, will serve as Executive Chairman of the combined company's Board of Directors, Steve Lundy will become the Chief Executive Officer of the combined company and Jeff McGonegal will continue as CFO. The initial combined board will consist of seven members with four from Strand LS and three from Venaxis.
Commenting on the transaction, Dr. Vijay Chandru said, "On behalf of the Strand LS shareholders, we believe that this transaction represents an attractive opportunity for Strand Life Sciences, as an agile innovator in clinical genomics, to combine forces with Venaxis, a public company in the United States with experienced executives and board members to help it rapidly expand market adoption of StrandAdvantage™ and other future product offerings."
"We are pleased to announce this transaction and are excited by the significant opportunity we believe it presents for shareholders of Venaxis and Strand LS," said Steve Lundy, Chief Executive Officer of Venaxis, Inc. "The combined company will benefit from Strand Life Sciences' 15 year successful history of technological expertise in genomic profiling, bioinformatics and data curation. Our initial focus will be to improve patient outcomes through the use of the StrandAdvantage pan-cancer gene panel, which was commercially launched in the United States in 2015. The combined company is expected to be focused on the continued commercialization of StrandAdvantage, as well as the development of additional oncology-related diagnostics."
Raymond James & Associates, Inc. and Oppenheimer & Co. Inc. are acting as joint financial advisors to Strand LS and Baker & Hostetler LLP is acting as legal counsel for Strand LS. Ballard Spahr LLP is acting as legal counsel to Venaxis.
Conference Call
Venaxis and Strand LS will host an investor conference call to discuss the transaction on Wednesday, January 27, 2016, at 8:30 a.m. ET. The conference call will be hosted by Steve Lundy, President and CEO of Venaxis, Inc.
At least. APPY was already worth .71 per share before the Strand LS merger news. This is going to help us shareholders enormously ahead IMO. Holding for the big $$$ ahead. Strand LS is a great company. That is worth some big $$$.
I think this merger could be great for us even though I just took a position today. I like the fact that they are trading below book value. I think shortly this could be trading pretty steady in the 50-60 cent range.
The longs here have posted a lot of good DD IMO. I am holding for much bigger $$$. I know day traders ended up frustrated or sold at a loss. That does not bother me. APPY is worth a heck of a lot more than any PPS it saw today IMO.
I'll keep my fingers crossed.
Tomorrow should be a better day. The overall markets hampered us IMO. News should spread and seeking alpha should be on the APPY news and do another write up IMO.
It looks like they have been holding APPY in a range to fill a large order IMO. Once they let her go we should run up fast.
Few shaky day traders here IMO taking their losses from buying APPY higher this AM. They look to have sold all their shares into the bid. .30 break should come soon IMO.
APPY should breakout solid above .30 soon. I expect to see a chase soon with massive bid supports and a break at .33 then we run to see if we break the HOD into the close IMO. When seekingalpha does articles they bring in big volume and dollars. IMO we will see something from them anytime ahead since they just did one 2 to 3 days ago with book value at .71 now they should want to update on todays news.
Would like to see it break and hold above 30 here but its having a hard time.
Welcome. Be on the lookout for sudden volume breakouts above on the APPY charts. I expect seekingalpha will be updating the article they did a couple days ago after todays big news. A large buyer bought 250K shares at .33 in a block trade pre market and I expect we will see a lot more of those type of buyers ahead.
I just bought my first lot at .2994
Followers
|
68
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2109
|
Created
|
08/29/07
|
Type
|
Free
|
Moderators |
http://www.aspenbiopharma.com/
http://finance.yahoo.com/q/h?s=APPY
http://moneycentral.msn.com/ownership?Holding=5%25+Ownership&Symbol=APPY
AspenBio Pharma, Inc. (APPY) is an emerging bio-pharmaceutical company dedicated to the discovery; development, manufacture, and marketing of novel proprietary products that have large worldwide market potential. We were originally formed in August 2000, as a Colorado corporation to produce purified proteins for diagnostic applications and have successfully leveraged our foundational science and technology expertise to rapidly develop a pipeline of new products. Today, the Company is primarily focused on advancing towards commercialization, our recently patented blood-based human diagnostic test, AppyScore™ to aid in the diagnosis of human appendicitis and several novel reproduction drugs for use in high value animals.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |